Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response
Journal of Internal Medicine · 2024-02 · 295 (2) · 229-241
DOI: 10.1111/joim.13742 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, online erschienen am 13.11.2023. Verfasst von Olisaemeka D Ogbue und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Cytopenia, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Splenectomy is commonly used to treat refractory immune–mediated cytopenia, but there are no established factors that are associated with response to the procedure.
Objectives
A cohort study was conducted to evaluate the hematologic and surgical outcomes of splenectomy in adult patients with immune cytopenias and identify preoperative factors associated with response.
Methods
Data from the Cleveland Clinic Foundation for 1824 patients aged over 18 who underwent splenectomy from 2002 to 2020 were analyzed.
Results
The study found that the most common indications for splenectomy were immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia, with a median age of 55 years and median time from diagnosis to splenectomy of 11 months. Hematologic response rates were 74% overall, with relapse in 12% of cases. Postsplenectomy discordant diagnoses were present in 13% of patients, associated with higher relapse rates. Surgery‐related complications occurred in 12% of cases, whereas only 3% of patients died from disease complications. On univariate analysis, preoperative factors associated with splenectomy treatment failure were ≥3 lines of pharmacologic treatment, whereas isolated thrombocytopenia, primary ITP, and age ≤40 years had a strong association with response. The multivariable regression confirmed that treatment failure with multiple lines of medical therapy was associated with the failure to respond to splenectomy.
Conclusion
Overall, the study demonstrates that splenectomy is an effective treatment option for immune‐mediated cytopenias with a low complication rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Hematology and Oncology, Yale University, New Haven, Connecticut, USA.
- Department of General Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
ORCID-Profile: Olisaemeka D Ogbue
Förderung
- NHLBI NIH HHS
Zitieren
APA
Ogbue, O. D., Bahaj, W., Kewan, T., Ahmed, R., Dima, D., Willimas, N., Durmaz, A., Visconte, V., Maskal, S. M., Gurnari, C., Steven, R., & Maciejewski, J. P. (2024). Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response. Journal of Internal Medicine, 295(2), 229-241. https://doi.org/10.1111/joim.13742
Vancouver
Ogbue OD, Bahaj W, Kewan T, Ahmed R, Dima D, Willimas N, et al. Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response. Journal of Internal Medicine. 2024;295(2):229-241. doi:10.1111/joim.13742
BibTeX
@article{Ogbue2024,
author = {Ogbue, Olisaemeka D and Bahaj, Waled and Kewan, Tariq and Ahmed, Ramsha and Dima, Danai and Willimas, Nakisha and Durmaz, Arda and Visconte, Valeria and Maskal, Sara M and Gurnari, Carmelo and Steven, Rosenblatt and Maciejewski, Jaroslaw P},
title = {Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response},
journal = {Journal of Internal Medicine},
year = {2024},
volume = {295},
number = {2},
pages = {229--241},
doi = {10.1111/joim.13742}
}
EUVIMED